Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
Oracle Corporation's cloud ERP for SMBs (40,000+ customers, 219 countries); NetSuite Next's Ask Oracle natural language AI assistant (SuiteWorld 2025), single-platform financial/CRM/inventory competing with SAP Business One.
NetSuite is a San Mateo, California and Austin, Texas-based cloud enterprise resource planning (ERP) platform and business unit of Oracle Corporation (NYSE: ORCL) — serving over 40,000 customers in 219 countries and territories with cloud-native financial management, CRM, inventory, supply chain, human capital management, and e-commerce applications designed for small-to-midsize businesses and rapidly growing enterprises that need unified business management software from a single cloud platform. NetSuite was founded in 1998 as NetLedger (one of the world's first cloud-based ERP systems) and acquired by Oracle in 2016 for $9.3 billion. Oracle's platform integration — connecting NetSuite to Oracle Cloud Infrastructure (OCI), Oracle Analytics Cloud, and Oracle's AI layer — enables NetSuite to leverage hyperscale compute, data warehousing, and generative AI capabilities that independent ERP vendors cannot build at equivalent cost. At SuiteWorld 2025, NetSuite unveiled NetSuite Next, featuring Ask Oracle — a natural language AI assistant enabling business users to search records, navigate workflows, analyze financial data, and trigger business actions across the entire NetSuite dataset through conversational queries rather than menu navigation — advancing toward autonomous AI-driven business management. The Oracle leadership transition (co-CEOs Clay Magouyrk and Mike Sicilia replacing Safra Catz) underscores Oracle's commitment to accelerating cloud product innovation across NetSuite, Oracle Cloud ERP (Fusion), and Oracle's SaaS portfolio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.